Comera Life Sciences Holdings, Inc. announced the expansion of its Woburn, Mass. operations with a ribbon-cutting ceremony. The space at 12 Gill St.

in Woburn, Mass., spans over 5,000 square feet and includes an expanded laboratory space for R&D activities as well as new executive offices. Comera is developing a portfolio of proprietary injectable therapeutics – called subcutaneous (SQ) therapeutics – with the goal of making it possible for patients to administer medications that historically have been administered only by intravenous (IV) infusion. The company applies its team's deep knowledge of formulation science and technology to transform essential biologic medicines from IV to SQ forms, which has the potential to spare patients long trips to a hospital or infusion center, where they may stay for hours to receive treatment.

The expansion is the latest milestone achieved by Comera this year. The company made its debut as a publicly traded company on the Nasdaq index in May.